Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocelluar Carcinoma

This study has been terminated.
(lack of progress)
Sponsor:
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
NCT00767936
First received: October 3, 2008
Last updated: October 9, 2013
Last verified: October 2013

October 3, 2008
October 9, 2013
March 2008
March 2013   (final data collection date for primary outcome measure)
identify mutations in the hepatitis B virus genome that predisposes these high risk individuals to the development of liver cancer [ Time Frame: one time ] [ Designated as safety issue: No ]
We will be using blood specimens collected through another protocol
Not Provided
Complete list of historical versions of study NCT00767936 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocelluar Carcinoma
Viral and Host Factors Associated With Development of Hepatitis B Virus-related Hepatocellular Carcinoma

Adult liver cancer is the third leading cause of cancer deaths worldwide. The major risk factor for liver cancer is hepatitis B virus (HBV) infection. The purpose of the study is to sequence the HBV genome in patients with chronic HBV infection, and in patients with liver cancer resulting from chronic HBV infection. The goal is to identify mutations in the HBV genome that predisposes these high risk individuals to the development of liver cancer.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

blood

Non-Probability Sample

liver cancer and non-cancer liver conditions

  • Liver Cancer
  • Hepatitis B
  • Hepatitis C
  • Hepatobiliary Cancers Liver
  • Hepatobiliary Cancers
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
135
September 2013
March 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:1. Patients diagnosed with liver cancer based on biopsy or serum AFP level, associated with characteristic hypervascular liver tumors on triphasic spiral CT scan or MRI.

2. Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or nodular hyperplasia.

3. Patients with hepatitis B or hepatitis C viral infections not associated with liver cancer.

Exclusion Criteria:No other patients except those listed above will be recruited. Additionally, patients will be excluded if, upon looking through their medical records, information required for data analysis are missing.

Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00767936
HEP0013, 98795, SU-05222008-1183
Not Provided
Stanford University
Stanford University
Not Provided
Principal Investigator: Samuel So Stanford University
Stanford University
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP